Lee, Jin-Soo
(Dept. of Oriental Clinical Oncology, College of Oriental Medicine, Kyung-Hee University)
Park, Hyeong-Jun (Dept. of Oriental Clinical Oncology, College of Oriental Medicine, Kyung-Hee University) Chae, Jean (Dept. of Oriental Clinical Oncology, College of Oriental Medicine, Kyung-Hee University) Kim, Kyung-Suk (Dept. of Oriental Internal Medicine, Kyung-Hee University Hospital at Gangdong) Jung, Hyun-Sik (Dept. of Oriental Internal Medicine, Kyung-Hee University Hospital at Gangdong) Lee, Sang-Hun (Dept. of Oriental Internal Medicine, Kyung-Hee University Hospital at Gangdong) Choi, Won-Choel (Dept. of Oriental Clinical Oncology, College of Oriental Medicine, Kyung-Hee University) Cheon, Seong-Ha (Division of Hemato-Oncology, Dept. of Internal Medicine, Kyung-Hee University Hospital at Gangdong) |
1 | Hanna N SF, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589-97. DOI ScienceOn |
2 | Chang MH AJ, Lee J, Kim KH, Park YH, Han J, Ahn MJ, et al. The efficacy of pemetrexed as a third-or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer. Lung Cancer. 2010;69:323-9. DOI ScienceOn |
3 | Sun JM LK, Kim JH, Kim YJ, Yoon HI, Lee JH, Lee CT, et al. Efficacy and toxicity of pemetrexed as a third-line treatment for nonsmall cell lung cancer. Jpn J Clin Oncol. 2009;39:27-32. |
4 | Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47. DOI ScienceOn |
5 | Richardson MA ST, Palmer JL, Greisinger A, Singletary SE. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol. 2000;18:2505-14. |
6 | Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S, Gitten R, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-smallcell lung cancer. J Clin Oncol. 2002;20:1335-43. DOI ScienceOn |
7 | Lee SK, Jung HS, Eo WK, Lee SY, Kim SH, Shim BS. Rhus verniciflua Stokes extract as a potential option for treatment of metastatic renal cell carcinoma: report of two cases. Ann Oncol. 2010;21:1383-5. DOI ScienceOn |
8 | Lee SH, Choi WC, Kim KS, Park JW, Yoon SW. Shrinkage of gastric cancer in an elderly patient who received Rhus verniciflua Stokes extract. J Altern Complement Med. 2010;16:497-500. DOI ScienceOn |
9 | Kim HR, Kim KS, Jung HS, Choi WC, Eo WK, Cheon SH. A case of recurred hepatocellular carcinoma refractory to doxorubicin after liver transplantation showing response to herbal medicine product, Rhus verniciflua Stokes extract. Integr Cancer Ther. 2010;9:100-4. DOI ScienceOn |
10 | Lee SH, Kim KS, Choi WC, Yoon SW. Successful outcome of advanced pulmonary adenocarcinoma with malignant pleural effusion by the standardized Rhus verniciflua stokes extract: a case study. Explore (NY). 2009;5:242-4. DOI ScienceOn |
11 | Shepherd FA RPJ, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-32. DOI ScienceOn |
12 | Yoo HT RJ. Compendium of prescriptions from the countryside(Hyangyakjipseongbang). Seoul: Hangrimchulpansa; 1977, p. 1433-640. |
13 | Choi WC LJ, Lee EO et al. Study on antiangiogenic and antitumor activities of processed Rhus verniciflua Stokes extract. Korean J Oriental Physiol Pathol. 2006;20:1-5. |
14 | Kook SH SY, Chung SW, et al. Caspase-independent death of human osteosarcoma cells by flavonoids is driven by p53-mediated mitochondrial stress and nuclear translocation of AIF and endonuclease G. Apoptosis. 2007;12:1289-98. DOI ScienceOn |
15 | Lee JC, Kim J, Jang YS. Ethanol-eluted extract of Rhus verniciflua stokes inhibits cell growth and induces apoptosis in human lymphoma cells. J Biochem Mol Biol. 2003;36:337-43. DOI |
16 | Sandler A GR, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, at al. Paclitaxel -carboplatin alone or with bevacizumab for non -small-cell lung cancer. N Engl J Med. 2006;355:2542-50. DOI ScienceOn |
17 | Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, et al. CISCA (CISplatin versus CArboplatin) Meta-analysis Group. Cisplatinversus carboplatin-based chemotherapy in firstline treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99:847-57. DOI ScienceOn |
18 | Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2004;22:3852-9. DOI ScienceOn |
19 | Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. CA Cancer J Clin. Cancer statistics. 2008;58:71-96. DOI ScienceOn |
20 | Pirker R PJ, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, et al, FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009;273:1525-31. |
21 | Stinchcombe TE SM. Considerations for second -line therapy of non-small cell lung cancer. Oncologist. 2008;13:28-36. DOI |
22 | Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095-103. |
23 | Schiller JH HD, Belani CP, Langer C, Sandler A, Krook J, Zhu J, et al; Eastern CooperativeOncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-8. DOI ScienceOn |
24 | Mok TS WY, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-57. DOI ScienceOn |
25 | Yoo KY. Cancer control activities in the Republic of Korea. Jpn J Clin Oncol. 2008;38:327-33. DOI ScienceOn |
![]() |